View Future GrowthIcade 과거 순이익 실적과거 기준 점검 0/6Icade 의 수입은 연평균 -31.4%의 비율로 감소해 온 반면, REITs 산업은 연평균 5.8%의 비율로 증가했습니다. 매출은 연평균 2.9%의 비율로 감소해 왔습니다.핵심 정보-31.35%순이익 성장률-31.46%주당순이익(EPS) 성장률REITs 산업 성장률19.39%매출 성장률-2.86%자기자본이익률-3.23%순이익률-9.20%다음 순이익 업데이트21 Jul 2026최근 과거 실적 업데이트공시 • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026공시 • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026공시 • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025공시 • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025공시 • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024공시 • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024모든 업데이트 보기Recent updates공시 • May 04Icade, Annual General Meeting, Jun 10, 2026Icade, Annual General Meeting, Jun 10, 2026. Location: immeuble coeur deense, tour b espace comet, 24eme etage, 100 esplanade du general de gaulle, paris la defense cedex France공시 • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026공시 • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026공시 • Apr 05Icade, Annual General Meeting, May 13, 2025Icade, Annual General Meeting, May 13, 2025. Location: immeuble coeur defense, tour b espace comet, 24eme etage 100 esplanade du general de gaulle, paris France공시 • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025공시 • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025공시 • Feb 19Icade, Annual General Meeting, Apr 19, 2024Icade, Annual General Meeting, Apr 19, 2024.공시 • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024공시 • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024공시 • Oct 23Icade to Report Fiscal Year 2023 Results on Feb 19, 2024Icade announced that they will report fiscal year 2023 results Pre-Market on Feb 19, 2024공시 • Sep 18Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)공시 • Jul 07Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders.Primonial REIM and Société Générale Assurances entered into an exclusivity agreement to acquire 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on March 13, 2023. As of June 13, 2023, Primonial REIM and Société Générale Assurances entered into a definitive agreement to acquire 37.312% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders. Under the terms of transaction, €1.1 billion in Icade Santé shares to be sold to funds managed by Primonial and €100 million in Icade Santé shares to be sold to Société Générale Assurances, increasing its stake in Icade Santé. In addition, €200 million in shares would be repurchased by Icade Santé from Icade followed by their cancellation. As part of this stage, Icade Santé has secured €550 million in bank financing from Société Générale and BNP Paribas to finance the €200 million in capital reduction, as well as the repayment of the €50 million shareholder loan from Icade and the refinancing of the €300million bridge-to-bond facility entered into in March 2022. Upon completion of this first stage, Icade would lose control of Icade Santé, resulting in the deconsolidation of the subsidiary in the Icade Group’s consolidated financial statements. In addition, Primonial REIM would take over the management of the portfolio from the closing date. Lazard-Natixis acted asfinancial advisor to Icade (ENXTPA:ICAD). The Boards of Directors of Icade Santé and Icade were consulted in advance and, after examining the potential conflicts of interest, unanimously approved the transaction in accordance with the applicable provisions, in particular the rules governing regulated related party agreements. Transaction is subject to the signing of the final agreements once the process of informing and consulting Icade’s employee representative bodies has been completed and the regulatory conditions precedent have been met. These include confirmation by the French Financial Markets Authority (AMF) that the transaction will not give rise to a buyout offer with squeeze-out for Icade’s share capital, pursuant to Article 236-6 of the AMF’s general regulations. The first stage of the transaction, which should be completed before the end of July 2023. Icade’s remaining stake in Icade Santé is expected to be sold by the end of 2025, mainly to funds managed by Primonial REIM or to investors identified by Primonial REIM based on Icade Santé’s most recently published EPRA NTA on the sale date. The cash generated by this transaction will help Icade to fortify its balance sheet and seize potential growth opportunities. As of July 5, 2023. Icade Completes First Stage In Sale Of Icade Sante For €1.4 Billion. The Legal advisor, White & Case team in Paris which advised Icade Santé on the transaction was led by partners Thomas Le Vert and Jean Paszkudzki and included partners Raphaël Richard, Brice Engel and Alexandre Jaurett. The White & Case team in Paris which advised the minority shareholders Predica, Sogecap and Cardif was led by partner Nathalie Nègre-Eveillard. Gauthier Blanluet, Nicolas de Boynes and Alexis Madec of Sullivan & Cromwell LLP acted as accountant advising Icade and Icade Santé on the tax aspects of the transaction. SG Corporate & Investment Banking acted as Financial advisor for Primonial REIM. Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on July 5, 2023.공시 • Jun 06Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS.Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS on June 5, 2023. Transaction is subject to approval of regulatory and competing authority. Elodie Cavazza and Fabien Charmasson of Jeausserand-Audouard acted as legal advisor to Coriance .공시 • May 18Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD).Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD) on May 17, 2023. The transaction will cover the entire AMO and EXPERTISE SANTE scope, with the exception of a few contracts in the West Indies, Guyana, Reunion and a medical contract. This sale should be effective on June 30, 2023. Xavier Norlain and Aymeric Robine of Shearman & Sterling LLP acted as advisor to OTEIS Group.공시 • Jan 05An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million.An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million on November 28, 2022. The Michigan Garden project is scheduled for completion in Q4 2024 and will generate €108 millon in revenue. An undisclosed buyer completed the acquisition of Michigan Garden Project from Icade SA (ENXTPA:ICAD) on November 28, 2022.공시 • Dec 15+ 2 more updatesIcade SA to Report Q1, 2023 Results on Apr 24, 2023Icade SA announced that they will report Q1, 2023 results at 9:00 AM, Central European Standard Time on Apr 24, 2023공시 • Dec 14Icade SA to Report Fiscal Year 2022 Results on Feb 20, 2023Icade SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Feb 20, 2023매출 및 비용 세부 내역Icade가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:CDMG.F 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 251,337-123327030 Sep 251,338-155331030 Jun 251,339-187334031 Mar 251,376-231335031 Dec 241,412-275336030 Sep 241,468-614339030 Jun 241,523-953343031 Mar 241,524-1,121355031 Dec 231,525-1,289367030 Sep 231,494-1,116370030 Jun 231,464-944372031 Mar 231,467-657367031 Dec 221,469-370361030 Sep 221,496-61415030 Jun 221,524249468031 Mar 221,586324425031 Dec 211,648399382030 Jun 211,640280228031 Mar 211,534178225031 Dec 201,42976222030 Jun 201,458259224031 Mar 201,485278221031 Dec 191,512298218030 Sep 191,587235215030 Jun 191,662173212031 Mar 191,717165220031 Dec 181,773156229030 Sep 181,714137229030 Jun 181,655118230031 Mar 181,642142227031 Dec 171,629165224030 Jun 171,596106219031 Mar 171,54275212031 Dec 161,48745205030 Jun 161,391-101204031 Mar 161,411-144205031 Dec 151,431-187206030 Jun 151,649821940양질의 수익: CDMG.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: CDMG.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CDMG.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 31.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CDMG.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CDMG.F은 수익성이 없어 지난 해 수익 성장률을 REITs 업계(-31.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CDMG.F는 현재 수익성이 없으므로 자본 수익률이 음수(-3.23%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YReal-estate 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 17:13종가2026/05/05 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Icade는 21명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Celine HuynhBarclaysPaul MayBarclaysCeline HuynhBarclays18명의 분석가 더 보기
공시 • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026
공시 • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026
공시 • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
공시 • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025
공시 • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024
공시 • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024
공시 • May 04Icade, Annual General Meeting, Jun 10, 2026Icade, Annual General Meeting, Jun 10, 2026. Location: immeuble coeur deense, tour b espace comet, 24eme etage, 100 esplanade du general de gaulle, paris la defense cedex France
공시 • Jan 14+ 2 more updatesIcade to Report Q3, 2026 Results on Oct 20, 2026Icade announced that they will report Q3, 2026 results at 6:00 PM, Central European Standard Time on Oct 20, 2026
공시 • Oct 23Icade to Report Fiscal Year 2025 Results on Feb 17, 2026Icade announced that they will report fiscal year 2025 results After-Market on Feb 17, 2026
공시 • Apr 05Icade, Annual General Meeting, May 13, 2025Icade, Annual General Meeting, May 13, 2025. Location: immeuble coeur defense, tour b espace comet, 24eme etage 100 esplanade du general de gaulle, paris France
공시 • Jan 07+ 2 more updatesIcade to Report Q3, 2025 Results on Oct 22, 2025Icade announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
공시 • Oct 21Icade to Report Fiscal Year 2024 Results on Feb 18, 2025Icade announced that they will report fiscal year 2024 results After-Market on Feb 18, 2025
공시 • Dec 14+ 1 more updateIcade to Report Q1, 2024 Results on Apr 22, 2024Icade announced that they will report Q1, 2024 results at 7:00 AM, Central European Standard Time on Apr 22, 2024
공시 • Nov 23Icade to Report First Half, 2024 Results on Jul 22, 2024Icade announced that they will report first half, 2024 results on Jul 22, 2024
공시 • Oct 23Icade to Report Fiscal Year 2023 Results on Feb 19, 2024Icade announced that they will report fiscal year 2023 results Pre-Market on Feb 19, 2024
공시 • Sep 18Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)Icade(ENXTPA:ICAD) dropped from FTSE All-World Index (USD)
공시 • Jul 07Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders.Primonial REIM and Société Générale Assurances entered into an exclusivity agreement to acquire 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on March 13, 2023. As of June 13, 2023, Primonial REIM and Société Générale Assurances entered into a definitive agreement to acquire 37.312% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders. Under the terms of transaction, €1.1 billion in Icade Santé shares to be sold to funds managed by Primonial and €100 million in Icade Santé shares to be sold to Société Générale Assurances, increasing its stake in Icade Santé. In addition, €200 million in shares would be repurchased by Icade Santé from Icade followed by their cancellation. As part of this stage, Icade Santé has secured €550 million in bank financing from Société Générale and BNP Paribas to finance the €200 million in capital reduction, as well as the repayment of the €50 million shareholder loan from Icade and the refinancing of the €300million bridge-to-bond facility entered into in March 2022. Upon completion of this first stage, Icade would lose control of Icade Santé, resulting in the deconsolidation of the subsidiary in the Icade Group’s consolidated financial statements. In addition, Primonial REIM would take over the management of the portfolio from the closing date. Lazard-Natixis acted asfinancial advisor to Icade (ENXTPA:ICAD). The Boards of Directors of Icade Santé and Icade were consulted in advance and, after examining the potential conflicts of interest, unanimously approved the transaction in accordance with the applicable provisions, in particular the rules governing regulated related party agreements. Transaction is subject to the signing of the final agreements once the process of informing and consulting Icade’s employee representative bodies has been completed and the regulatory conditions precedent have been met. These include confirmation by the French Financial Markets Authority (AMF) that the transaction will not give rise to a buyout offer with squeeze-out for Icade’s share capital, pursuant to Article 236-6 of the AMF’s general regulations. The first stage of the transaction, which should be completed before the end of July 2023. Icade’s remaining stake in Icade Santé is expected to be sold by the end of 2025, mainly to funds managed by Primonial REIM or to investors identified by Primonial REIM based on Icade Santé’s most recently published EPRA NTA on the sale date. The cash generated by this transaction will help Icade to fortify its balance sheet and seize potential growth opportunities. As of July 5, 2023. Icade Completes First Stage In Sale Of Icade Sante For €1.4 Billion. The Legal advisor, White & Case team in Paris which advised Icade Santé on the transaction was led by partners Thomas Le Vert and Jean Paszkudzki and included partners Raphaël Richard, Brice Engel and Alexandre Jaurett. The White & Case team in Paris which advised the minority shareholders Predica, Sogecap and Cardif was led by partner Nathalie Nègre-Eveillard. Gauthier Blanluet, Nicolas de Boynes and Alexis Madec of Sullivan & Cromwell LLP acted as accountant advising Icade and Icade Santé on the tax aspects of the transaction. SG Corporate & Investment Banking acted as Financial advisor for Primonial REIM. Primonial REIM and Société Générale Assurances completed the acquisition of 63% stake in Icade Santé SAS from Icade (ENXTPA:ICAD) and its Minority Shareholders for €1.4 billion on July 5, 2023.
공시 • Jun 06Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS.Vauban Infrastructure Partners and Icade (ENXTPA:ICAD) agreed to acquire A2A Coriance SAS on June 5, 2023. Transaction is subject to approval of regulatory and competing authority. Elodie Cavazza and Fabien Charmasson of Jeausserand-Audouard acted as legal advisor to Coriance .
공시 • May 18Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD).Oteis France Sas agreed to acquire AMO and EXPERTISE SANTE activity from Icade (ENXTPA:ICAD) on May 17, 2023. The transaction will cover the entire AMO and EXPERTISE SANTE scope, with the exception of a few contracts in the West Indies, Guyana, Reunion and a medical contract. This sale should be effective on June 30, 2023. Xavier Norlain and Aymeric Robine of Shearman & Sterling LLP acted as advisor to OTEIS Group.
공시 • Jan 05An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million.An undisclosed buyer acquired Michigan Garden Project from Icade SA (ENXTPA:ICAD) for €108 million on November 28, 2022. The Michigan Garden project is scheduled for completion in Q4 2024 and will generate €108 millon in revenue. An undisclosed buyer completed the acquisition of Michigan Garden Project from Icade SA (ENXTPA:ICAD) on November 28, 2022.
공시 • Dec 15+ 2 more updatesIcade SA to Report Q1, 2023 Results on Apr 24, 2023Icade SA announced that they will report Q1, 2023 results at 9:00 AM, Central European Standard Time on Apr 24, 2023
공시 • Dec 14Icade SA to Report Fiscal Year 2022 Results on Feb 20, 2023Icade SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Feb 20, 2023